 |
 |
 |
 |
 |
 |
 |
 |
E-Mail
ShareEntry Inhibitors in Development
- An Anti-Inflammatory Antiretroviral? CCR5/CCR2 Antagonist TBR-652 Monotherapy Study Results: A Blog Entry by Myles Helfand (July 19, 2010)
In The XVIII International AIDS Conference, from The Body PRO - TBR-652: A CCR5 Antagonist -- With Anti-Inflammatory Properties? (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Anatomy of a Failure: Vicriviroc (March 8, 2010)
Part of a CROI 2010 wrap-up discussion with Joel Gallant, M.D., M.P.H.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - New CCR5 Antagonist TBR-652 Shows Good Antiviral Activity in Early Study (February 18, 2010)
From aidsmap.com - CCR5 Antagonist Vicriviroc Fails to Surpass Potent Background Regimen (February 18, 2010)
From aidsmap.com - Why Vicriviroc Failed in Its Phase 3 Trials -- and What It May Mean for Future Studies in HIV Treatment-Experienced People (Feb. 17, 2010; 11:36 a.m. Pacific Time)
A blog entry from CROI 2010 by Myles Helfand.
In The 17th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Peering in the Pipeline (Summer 2009)
To read PDF, click here.
In Achieve, from ACRIA and GMHC - Incyte Halts Development of Promising New CCR5 Drug (April 10, 2008)
From Project Inform - CCR5 Inhibitors in Development: New Data on SCH532706 and Vicriviroc (February 3, 2008)
In 15th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Schering-Plough Launches Phase III Trials of Experimental Antiretroviral Vicriviroc (September 19, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - CCR5 Entry Inhibitors: Vicriviroc (July 25, 2007)
Edwin DeJesus takes a look at recent data on vicriviroc, a CCR5 entry inhibitor currently being studied in treatment-experienced patients.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - CCR5 Antagonists: INCB009471 and Vicriviroc (July 24, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - Orally Bioavailable Fusion Inhibitors in Development (July 23, 2007)
In The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO - The Last Word on Aplaviroc: A CCR5 Antagonist With Poor Efficacy (December 19, 2006)
In 8th International Congress on Drug Therapy in HIV Infection - No Difference in HAART Response in Patients With X4-Using HIV (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy - Aplaviroc's Potency Against HIV Is Linked to Its Slow Dissociation From the CCR5 Receptor (August 17, 2006)
In XVI International AIDS Conference - Co-Receptor Conundrum: The Challenges of Turning Theory Into Reality (April 2006)
At the moment, there are many more questions than answers about an investigational class of drugs known as co-receptor inhibitors.
To read PDF, click here.
In TAGline, from Treatment Action Group - Entry Inhibitors in Development (March 30, 2006)
An overview from Edwin DeJesus, M.D.
From The Body - Biotech Firm Creates Genetically Modified Immune Cells That Resist HIV Infection in Vitro (December 20, 2005)
[Archived Article]
Sangamo aims to modify patients' immune cells to possess a CCR5 receptor mutation that may make them "uninfectable".
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - University of Arkansas Scientists Win $10.2 Million Grant to Block HIV Receptor (December 8, 2005)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - GlaxoSmithKline Stops All Clinical Trials of Entry Inhibitor Aplaviroc (October 25, 2005)
[Archived Article]
To read PDF, click here.
From GlaxoSmithKline - Liver Toxicity Halts Trials of CCR5 Antagonist Aplaviroc in Treatment-Naive Patients (September 19, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Vicriviroc (SCH 417690, SCH-D), a CCR5 Antagonist, Generally Well Tolerated and Effective in 14-Day Monotherapy Study (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - 873140, a CCR5 Antagonist, Displays Activity Against R5-Tropic Virus in Naive and Experienced Patients (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - The Antiviral Benefits of 873140, a CCR5 Antagonist (February 24, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - A New Era in HIV Treatment -- The Entry Inhibitors (January/February 2005)
[Archived Article]
Daniel S. Berger, M.D., reviews the concept behind the CCR5 inhibitor, a new type of entry inhibitor in development.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network - The X4 Files: CCR5 and CXCR4 Coreceptors (July/August 2004)
[Archived Article]
Several abstracts presented at AIDS 2004 examined these two sites on CD4 cells that may be targeted by a new class of antiretrovirals.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Entry Inhibitors in Development (July 2004)
[Archived Article]
Brief updates on PRO 542, SCH-D, UK-427,857 and GW-873140.
To read PDF, click here.
In Project Inform Perspective, from Project Inform - HIV Coreceptor Drugs on the Horizon (July/August 2004)
[Archived Article]
A summary of research on coreceptor inhibitors presented at AIDS 2004.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Drug Development News: CCR5 Blockers (May/June 2004)
[Archived Article]
Several are in clinical trials, but questions persist as to their usefulness in treatment-experienced patients.
In GMHC Treatment Issues, from Gay Men's Health Crisis - BMS 488043 (March/April 2004)
[Archived Article]
A review of the most recent studies regarding this attachment inhibitor in development that were presented at CROI 2004.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network - Receptor Blockers: GW873140, SCH-C, SCH-D (March/April 2004)
[Archived Article]
A quick look at data about these attachment inhibitors in development that was presented at CROI 2004.
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network - A Look at Antiretroviral Agents in Development -- An Attachment Inhibitor and Two CCR5 Receptor Antagonists (February 11, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - GW873140, a Promising CCR5 Inhibitor Candidate (February 11, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Co-Receptor Overview: CC-CCR5 and CXCR4 (Fusin) (January 2003)
[Archived Article]
To read PDF, click here.
From Project Inform - SCH-C Moves Ahead -- Carefully (September 2002)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis - Fusion Inhibitors (Summer/Autumn 2002)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - Entry Inhibitors (Summer/Autumn 2002)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - New Targets Bring New Challenges (March 2002)
[Archived Article]
A closer look at integrase and entry inhibitors.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Identification and Characterization of a Novel Inhibitor of HIV-1 Entry (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - The Next Target in Therapy: Viral Entry (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Development of CCR5 Antagonists as a New Class of Anti-HIV Therapeutic (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The Body PRO is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body PRO and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body PRO's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body PRO is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body PRO should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.